Infectious Diseases
Search for publications
Only original articles, editorials, guidelines.
-
Sánchez-Del Cojo M, López-Huertas MR, Díez-Fuertes F, Rodríguez-Mora S, Bermejo M, López-Campos G, Mateos E, Jiménez-Tormo L, Gómez-Esquer F, Díaz-Gil G, Alcamí J, Coiras M.
Changes in the cellular microRNA profile by the intracellular expression of HIV-1 Tat regulator: A potential mechanism for resistance to apoptosis and impaired proliferation in HIV-1 infected CD4+ T cells.
PLoS One . 12(10): . Number of citations: 22
-
Ghosn J, Bayan T, Meixenberger K, Tran L, Frange P, d'Arminio Monforte A, Zangerle R, de Mendoza C, Krastinova E, Porter K, Meyer L, Chaix ML, CASCADE Collaboration in EuroCoord.
CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY . 72(10): 2862-2868. Number of citations: 6
-
San-Juan R, Pérez-Montarelo D, Viedma E, Lalueza A, Fortún J, Loza E, Pujol M, Ardanuy C, Morales I, de Cueto M, Resino-Foz E, Morales-Cartagena MA, Fernández-Ruiz M, Rico A, Romero MP, Fernández de Mera M, López-Medrano F, Orellana MÁ, Aguado JM, Chaves F.
Pathogen-related factors affecting outcome of catheter-related bacteremia due to methicillin-susceptible Staphylococcus aureus in a Spanish multicenter study.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES . 36(10): 1757-1765. Number of citations: 9
-
Crespo M, Navarro J, Moreno S, Sanz J, Márquez M, Zamora J, Ocampo A, Iribaren JA, Rivero A, Llibre JM.
Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA . 35(8): 493-498. Number of citations: 3
-
Masiá M, Padilla S, Moreno S, Barber X, Iribarren JA, Del Romero J, Gómez-Sirvent JL, Rivero M, Vidal F, Campins AA, Gutiérrez F.
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach.
PLoS One . 12(9): . Number of citations: 10
-
Serrano-Villar S, Vázquez-Castellanos JF, Vallejo A, Latorre A, Sainz T, Ferrando-Martínez S, Rojo D, Martínez-Botas J, Del Romero J, Madrid N, Leal M, Mosele JI, Motilva MJ, Barbas C, Ferrer M, Moya A, Moreno S, Gosalbes MJ, Estrada V.
The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects.
Mucosal Immunology . 10(5): 1279-1293. Number of citations: 106
-
Fernández-Ruiz M, Guinea J, Lora-Pablos D, Zaragoza Ó, Puig-Asensio M, Almirante B, Cuenca-Estrella M, Aguado JM, CANDIPOP Project, GEIH-GEMICOMED (SEIMC) and REIPI.
Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance.
CLINICAL MICROBIOLOGY AND INFECTION . 23(9): . Number of citations: 21
-
Sanchez Conde M, Vivancos Gallego MJ, Moreno Guillen S.
Pre-exposure prophylaxis (PrEP) against HIV: efficacy, safety and uncertainties.
FARMACIA HOSPITALARIA . 41(5): 630-637.
-
Moreno Guillen S, Losa García JE, Berenguer Berenguer J, Martínez Sesmero JM, Cenoz Gomis S, Graefenhain R, Lopez Sanchez-Cambronero D, Parrondo Garcia FJ.
Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
FARMACIA HOSPITALARIA . 41(5): 601-610.
-
Pérez-Molina JA, López-Polín A, Treviño B, Molina I, Goikoetxea J, Díaz-Menéndez M, Torrús D, Calabuig E, Benito A, López-Vélez R.
6-year review of +Redivi: a prospective registry of imported infectious diseases in Spain.
JOURNAL OF TRAVEL MEDICINE . 24(5): . Number of citations: 40
-
Alpern JD, Lopez-Velez R, Stauffer WM.
Access to benznidazole for Chagas disease in the United States-Cautious optimism?
PLoS Neglected Tropical Diseases . 11(9): . Number of citations: 27
-
Fortún J, Gioia F.
Invasive candidiasis in the neutropenic patient.
Revista Espanola de Quimioterapia . 30 Suppl 1: 22-25. Number of citations: 6
-
Vivancos MJ, Gómez-Ayerbe C, Moreno S.
Highlights in HIV, 2016.
Revista Espanola de Quimioterapia . 30 Suppl 1: 13-15.
-
Geretti AM, Loutfy M, D'Arminio Monforte A, Latysheva I, Pérez Elías MJ, Rymer J, Boffito M.
Out of focus: tailoring the cascade of care to the needs of women living with HIV.
HIV MEDICINE . 18 Suppl 2: 3-17. Number of citations: 11
-
Navarro M, Monge-Maíllo B, Flores-Chavez MD, López-Vélez R.
Hunting hidden parasites: Trypanosoma cruzi.
LANCET . 390(10096): 724-726. Number of citations: 15
-
Poveda E, Hernández-Quero J, Pérez-Elías MJ, Ribas MA, Martínez-Madrid OJ, Flores J, Navarro J, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestaran A, García F, Paredes R.
Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.
HIV MEDICINE . 18(7): 482-489. Number of citations: 1
-
Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, Mallolas J, Crespo M, Téllez MJ, Quereda C, Sanz J, Barros C, Tural C, Santos I, Pulido F, Guardiola JM, Rubio R, Ortega E, Montes ML, Jusdado JJ, Gaspar G, Esteban H, Bellón JM, González-García J.
Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.
HEPATOLOGY . 66(2): 344-356. Number of citations: 51
-
Gudiol C, Royo-Cebrecos C, Abdala E, Akova M, Álvarez R, Maestro-de la Calle G, Cano A, Cervera C, Clemente WT, Martín-Dávila P, Freifeld A, Gómez L, Gottlieb T, Gurguí M, Herrera F, Manzur A, Maschmeyer G, Meije Y, Montejo M, Peghin M, Rodríguez-Baño J, Ruiz-Camps I, Sukiennik TC, Tebe C, Carratalà J, BICAR Study Group.
Efficacy of ß-Lactam/ß-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-ß-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY . 61(8): . Number of citations: 47